International Symposium on Juvenile Myelomonocytic Leukemia

描述（由申请人提供）：我们正在申请支持一个青少年髓细胞白血病（JMML）研究人员的年度科学会议。此外，还将邀请几位主治医生和患有这种疾病的儿童的家属参加。jml是一种侵袭性白血病，影响婴儿和幼儿。它是迅速致命的，对化疗的反应通常是短暂的。目前，唯一已知的治疗方法是通过造血干细胞移植实现的，这可能对这些幼儿的发育产生破坏性影响。在过去的几年中，已经取得了一些重要的科学突破，这些突破坚定地表明Ras/MAPK通路的过度激活是该疾病的起始事件。鉴于对致癌Ras在肿瘤中的作用的积极研究以及对这种致命疾病的改进治疗的需求，本次会议为基础科学研究者、临床科学家、监管科学家和受影响者的家庭成员提供了一个重要的场所，可以相互作用和合作。因此，jml基金会的年度研讨会有四个主要目标：1。分享JMML科学和临床研究的最新发展，由国内和国际领先的领域领导者进行高水平的演讲；2. 为规划和实施针对该病患者的创新临床试验提供场所；3. 促进JMML研究人员与患者维权人士之间的沟通；和4。提供一个论坛，让JMML的初级研究人员可以展示他们的工作，相互交流，并与该领域的高级研究人员交流。寻求连续五年的支持，与美国血液学学会一起召开会议。通过这种方式，我们将利用并继续在以前的会议期间建立成功的国际合作。2007年会议将于12月6日至7日在乔治亚州亚特兰大举行。本次会议的PI是Mignon Loh， MD，他是jml基金会的董事会成员。她和她的同事，博士。Christian Kratz和Kevin Shannon将在jml基金会的组织支持下计划会议。预计将有50至60名与会者出席。将特别关注来自代表性不足社区的初级研究人员、博士后研究员、临床医生和科学家。

DESCRIPTION (provided by applicant): We are requesting support for an annual scientific meeting for investigators studying juvenile myelomonocytic leukemia (JMML). In addition, several treating physicians and families of children afflicted with this disease will be invited to attend. JMML is an aggressive form of leukemia that affects infants and young children. It is rapidly fatal, and responses to chemotherapy are generally shortlived. Currently, the only known cures are achieved through hematopoietic stem cell transplants, which can have devastating developmental effects on these young children. Several important scientific breakthroughs have been made over the past several years that firmly implicate hyperactivation of the Ras/MAPK pathway as the initiating event in this disease. Given the active investigation of the role of oncogenic Ras in neoplasia and the need for improved therapies for this fatal disease, this meeting serves a critical venue in which basic science investigators, clinical scientists, regulatory scientists, and family members of those affected can interact and collaborate. The annual symposium of the JMML foundation thus has four major goals: 1. to share the latest developments in JMML scientific and clinical research by fostering high level presentations from leading national and international leaders in the field; 2. to provide a venue for planning and implementing innovative clinical trials for patients with this disease; 3. to facilitate communication between JMML investigators and patient advocates; and 4. to provide a forum in which junior investigators in JMML can present their work and interact with each other and with senior investigators in the field. Support is sought for five consecutive years, with meetings being held in conjunction with the American Society of Hematology. In this manner, we will capitalize on and continue successful international collaborations set during prior meetings. The 2007 meeting will be held December 6-7 in Atlanta, Georgia. The PI of this meeting is Mignon Loh, MD, who is a member of the board of directors of The JMML Foundation. She and her colleagues, Drs. Christian Kratz and Kevin Shannon will plan the meeting with organizational support from The JMML Foundation. A total of 50-60 participants are anticipated to attend. Special attention will be made to include junior investigators, post-doctoral fellows, and clinicians and scientists from underrepresented communities.